Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]

Cabozantinib most effective treatment for metastatic papillary kidney cancer

Dr Sumanta Pal - City of Hope, Duarte, USA

Cabozantinib most effective treatment for metastatic papillary kidney cancer ( Dr Sumanta Pal - City of Hope, Duarte, USA )

Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell...

Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology...

Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma ( Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA )

SEMS trial: result of a prospective, multi-institutional phase II clinical...

Dr Sia Daneshmand - University of Southern California, Los Angeles, USA

SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma ( Dr Sia Daneshmand - University of Southern California, Los Angeles, USA )

Challenges in nursing GU cancer patients during COVID-19

Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK

Challenges in nursing GU cancer patients during COVID-19 ( Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK )

Latest developments in the treatment of mRCC

Prof Javier Puente, Prof Jens Bedke, Prof James Larkin and Prof Viktor Grünwald

Latest developments in the treatment of mRCC ( Prof Javier Puente, Prof Jens Bedke, Prof James Larkin and Prof Viktor Grünwald )

Long term response to apalutamide and other updates impacting patients with...

Prof Axel Merseburger and Prof Matthew Smith

Long term response to apalutamide and other updates impacting patients with nmCRPC from ASCO GU 2021 ( Prof Axel Merseburger and Prof Matthew Smith )

mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early...

Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt...

mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early treatment? ( Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt Attard )

Diagnosis, testing and biomarkers in the individualisation of patient care with...

Prof Andrea Necchi and Prof Eva Compérat

Diagnosis, testing and biomarkers in the individualisation of patient care with FGFR mutated bladder cancer ( Prof Andrea Necchi and Prof Eva Compérat )

Nurse's perspective on PARP inhibitors and personalised medicine in prostate...

Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK

Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer ( Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK )

TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alterations and mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

ASCO GU 2021: Renal cancer roundup

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2021: Renal cancer roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

TITAN: Update and where next for patients with hormone sensitive PC

Prof Axel Merseburger and Prof Kim Chi

TITAN: Update and where next for patients with hormone sensitive PC ( Prof Axel Merseburger and Prof Kim Chi )

More from ecancer